Personalized cancer vaccines are designed for an individual patient rather than a broad population. Most target neoantigens, abnormal protein fragments created by mutations in tumor cells but absent from healthy tissues. Because these altered fragments can be recognized as foreign by T cells, they offer a way to direct the immune system toward malignant cells with greater precision than conventional cancer treatments. A typical development process begins with tumor and normal-tissue sequencing, followed by computational analysis to identify mutations that could generate recognizable peptides. The selected targets are then encoded in a vaccine platform, such as messenger RNA, synthetic peptides, DNA, or viral vectors. Although the concept is straightforward in principle, each stage contains variables that can influence the final treatment.

The first challenge is the quality and interpretation of tumor genomic data. Tumors are genetically diverse and often contain a mixture of malignant and nonmalignant cells, meaning that a mutation detected in a biopsy may not be present in every cancer cell. Samples can also differ in their purity, sequencing depth and storage conditions. Computational pipelines must distinguish genuine tumor mutations from technical errors and inherited variants, then determine which mutations are likely to produce peptides presented by the patient’s human leukocyte antigen molecules. These HLA proteins display intracellular protein fragments on the cell surface for inspection by T cells. Because HLA genes vary substantially between individuals, an antigen predicted to be visible in one patient may be poorly presented in another. Harmonized sequencing standards and prediction benchmarks are therefore essential for determining whether candidate neoantigens are truly comparable across studies.

A second concern is how researchers define a high-value neoantigen. Prediction algorithms commonly evaluate factors such as mutation type, gene expression, peptide binding to HLA molecules and the likelihood that T-cell receptors can recognize the displayed fragment. Yet a strong computational score does not guarantee an immune response. Some predicted peptides are produced inefficiently, degraded before reaching the cell surface or hidden by the tumor’s mechanisms of immune evasion. Others may be recognized only by a small population of T cells. The authors’ emphasis on harmonization highlights the need to combine computational predictions with experimental validation, including mass-spectrometry analysis of naturally presented peptides and functional tests using patient immune cells. Establishing shared criteria for evidence could reduce the number of weak targets entering clinical development.

The vaccine platform itself introduces another layer of variation. Messenger RNA vaccines can be manufactured rapidly and translated directly into antigenic proteins inside cells, while peptide vaccines require delivery systems and adjuvants to stimulate sufficient immune activation. Viral-vector vaccines use engineered viruses to carry tumor-antigen genes into cells, taking advantage of the strong innate and adaptive immune responses that viral infections naturally provoke. However, pre-existing immunity against a vector can limit its effectiveness, and repeated dosing may be affected by antibodies or T cells directed against the delivery virus rather than the tumor antigen. Each platform also differs in stability, manufacturing requirements, dose, timing and safety profile. Comparing these technologies requires common reporting standards that separate the effect of the antigen from the effect of the delivery system.

The third major issue is manufacturing speed and reliability. A personalized vaccine is produced for a specific patient, often after surgery or biopsy has provided sufficient tumor material. The treatment team must complete sequencing, antigen selection, design, production and quality control within a clinically useful window. Delays can be particularly consequential for patients with rapidly progressing disease. Manufacturing must also confirm the identity, purity, concentration and structural integrity of the vaccine product. For RNA-based approaches, for example, important variables include RNA sequence accuracy, chemical modification, encapsulation efficiency and resistance to degradation. For viral vectors, investigators must monitor infectivity, genetic stability, replication competence and the absence of unwanted contaminants. Harmonized release criteria could help ensure that a product made at one facility is equivalent in quality to a product made elsewhere.

The fourth challenge involves measuring immune responses in a consistent way. A vaccine may expand neoantigen-specific CD8-positive cytotoxic T cells, CD4-positive helper T cells, or both, but the presence of these cells in blood does not necessarily demonstrate that they can enter a tumor and destroy malignant cells. Researchers use tools including peptide–HLA multimer staining, interferon-gamma release assays, intracellular cytokine analysis, T-cell receptor sequencing and single-cell profiling. These methods provide different types of information and can produce different estimates of response magnitude. A patient may show a detectable immune response under one assay but not another, depending on the peptide concentration, cell culture conditions and definition of positivity. Shared reference materials, controls and reporting rules would make it easier to determine whether an immune response is robust, durable and clinically relevant.

Immune monitoring must also be connected to the biology of the tumor. Cancer cells can lose the targeted mutation, reduce antigen production or disrupt antigen presentation through defects in HLA molecules and associated processing machinery. The tumor microenvironment may further suppress immunity through regulatory T cells, myeloid-derived suppressor cells, inhibitory cytokines and checkpoint molecules such as PD-L1. For this reason, personalized vaccines are increasingly considered as components of combination treatment rather than stand-alone products. Checkpoint inhibitors may release brakes on activated T cells, while radiation or chemotherapy can alter antigen release and tumor visibility. Viral-vector vaccines may provide additional inflammatory signals that help recruit immune cells, but their effects must be distinguished from those of the accompanying therapies. Harmonized clinical designs are needed to identify which combinations truly improve outcomes.

The fifth area concerns clinical trials and regulation. Personalized vaccine studies often enroll relatively small numbers of patients because every treatment is individually designed, making conventional trial structures difficult to apply. Differences in cancer type, disease stage, prior therapy, tumor mutation burden and vaccine composition can complicate comparisons between studies. Investigators therefore need agreed definitions for endpoints, including feasibility, manufacturing success, immune response, recurrence-free survival and overall survival. Regulatory agencies must evaluate not only the final vaccine but also the computational pipeline used to select its targets and the manufacturing process used to produce it. A transparent framework could allow a platform to be validated once while individual vaccine sequences are assessed under controlled procedures, reducing duplication without compromising safety.

The authors’ message arrives as personalized oncology expands into a field where speed, precision and reproducibility must advance together. A vaccine that is biologically sophisticated but produced too slowly may not benefit a patient; a vaccine that generates immune cells but targets an irrelevant or poorly presented antigen may fail for biological reasons; and a promising clinical result that cannot be compared with other studies may delay progress across the field. Harmonization does not mean forcing every research group to use one technology. Instead, it means defining common standards for data quality, antigen selection, manufacturing, immune monitoring and clinical evaluation while preserving room for innovation. By organizing the challenges around five interconnected priorities, the review frames personalized cancer vaccines as an emerging medical system that requires coordination across genomics, immunology, bioinformatics, engineering and regulation. The prospect is not simply a faster way to make individualized vaccines, but a more reliable path toward determining which patients are most likely to benefit and why.

Subject of Research: Harmonization and standardization of personalized cancer vaccines for cancer immunotherapy, including neoantigen identification, vaccine platforms, manufacturing, immune monitoring and clinical evaluation.

Article Title: Take Five: harmonization in personalized cancer vaccines for cancer immunotherapy

Article References:

Cho, S., Lee, J., Lee, YM. et al. Take Five: harmonization in personalized cancer vaccines for cancer immunotherapy. Exp Mol Med (2026). https://doi.org/10.1038/s12276-026-01807-y

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s12276-026-01807-y

Keywords: personalized cancer vaccines, cancer immunotherapy, neoantigens, tumor sequencing, HLA presentation, viral vectors, messenger RNA vaccines, immune monitoring, vaccine manufacturing, clinical trial harmonization

Cells acquire mutations through a combination of external environmental insults—such as ultraviolet radiation from sunlight or carcinogens in tobacco smoke—and intrinsic errors during DNA replication and repair. These mutations often result in amino acid substitutions, altering proteins in subtle or profound ways. By meticulously analyzing close to 9,300 cancer genomes spanning various cancer types, researchers uncovered an unexpected order amid this molecular chaos. Nearly every tumor’s mutational landscape is dominated by one of five distinct amino acid substitution signatures, revealing a convergent protein-level consequence amidst vast genomic diversity.

This discovery goes beyond mere classification. Each substitution signature holds a unique code that influences how tumor proteins present themselves to immune cells. Some create neoantigens—novel peptides recognized as foreign by T cells—prompting a strong immune assault on the tumor. Conversely, other patterns generate less immunogenic neoantigens, enabling tumors to remain “cold” and evade immune surveillance, thereby resisting immunotherapies. This paradigm challenges the long-held assumption that the sheer number of mutations (mutational burden) predicts immunotherapy responsiveness, emphasizing instead the qualitative nature of mutational effects at the protein level.

Dr. Szilvia Juhász, leading the Cancer Microbiome Research Group at HCEMM, whose team contributed significantly to the study, explains, “Despite the complexity and diversity of mutational processes across cancers, their protein-level effects boil down to a limited set of recurring signatures. These fingerprints act like molecular barcodes, decisively shaping immune recognition and response to therapy.” Such insights offer a crucial lens for understanding the biological heterogeneity in immune engagement across tumors.

Notably, one particular signature associated with defects in DNA repair mechanisms, compounded by chemical exposures, has profound clinical significance. Tumors dominated by this pattern frequently display poor responses to immune checkpoint inhibitors, even when their mutational burden remains elevated. This dissociation between mutation quantity and immune responsiveness underscores that the functional consequences of mutations — rather than their mere existence — dictate therapeutic outcomes.

Co-first author Dr. Benjamin Papp from the HUN-REN Szeged Biological Research Centre stresses, “Evaluating mutational burden alone paints an incomplete picture. The nuanced, protein-altering consequences of specific mutations are essential for determining why many patients fail to benefit from immune-based therapies.” This reframing encourages a more detailed molecular stratification of tumors beyond simple mutation counting.

An intriguing aspect of the findings is the role of the patient’s own immune genetics in modulating tumor visibility. Variations in human leukocyte antigen (HLA) class I molecules, which present neoantigens on tumor cells, can influence the effectiveness of these distinct mutation fingerprints in engaging T cells. Certain HLA types prevalent in European populations appear to partially overcome the immune invisibility imposed by less immunogenic mutation patterns, suggesting a complex interplay between tumor genomics and host immunogenetics.

This intersection highlights the personalized nature of tumor immunity. Two patients harboring genetically similar tumors might experience starkly different immunotherapy outcomes based on their HLA repertoire and how it interacts with the tumor’s mutational signature. Dr. Máté Manczinger, who heads the Systems Immunology Research Group at the HUN-REN Szeged Biological Research Centre, summarizes, “Integrating tumor genomic profiles with the patient’s immunogenetic background is critical for the next generation of precision immunotherapies.”

Beyond its transformative scientific implications, this study offers tangible clinical and societal benefits. More precise predictions of which tumors will respond to immune checkpoint blockade or other immunotherapies could streamline treatment decisions, reduce exposure to ineffective therapies, and minimize adverse side effects. Early identification of non-responders would expedite alternative strategies, improving patient outcomes and cost-effectiveness in cancer care.

This pioneering research was a collaborative effort among the Systems Immunology Research Group at the HUN-REN Szeged Biological Research Centre, the HCEMM Cancer Microbiome Research Group, and the Evolutionary Systems Biology Research Group at the Biological Research Centre. The work exemplifies the power of interdisciplinary scientific synergy in addressing complex biomedical challenges.

Funded by prestigious grants under the European Horizon 2020 initiative and Hungarian governmental awards, including support from Semmelweis University, the University of Szeged, and the European Molecular Biology Laboratory, the study sets a new benchmark for integrating multi-omic data toward functional immunogenomics. The findings were published on January 28, 2026, in Molecular Systems Biology, marking a significant advance in the field of cancer immunology.

In sum, this research illuminates that a tumor’s immune detectability hinges not on mutation numbers alone but on the distinct protein-level “fingerprints” these mutations encode. This paradigm shift towards a qualitative understanding of mutation-driven immune engagement lays the groundwork for more personalized, effective immunotherapies tailored to both tumor genetic landscapes and patient-specific immune genotypes, heralding a new era in cancer treatment.

Subject of Research: Cells

Article Title: Five dominant amino acid substitution signatures shape tumour immunity

News Publication Date: 28-Jan-2026

Web References: http://dx.doi.org/10.1038/s44320-026-00193-x

Image Credits: Máté Manczinger, HUN-REN Szeged Biological Research Centre (BRC)

Keywords: Cancer immunology, DNA repair, Loss of function mutations, Immunogenicity, Cancer immunotherapy

Central to T cell recognition of tumors are two primary classes of antigens. Tumor-specific neoantigens arise from somatic mutations unique to cancer cells, exhibiting high immunogenicity and minimal expression in normal tissues. Such neoantigens offer exquisite specificity, reducing the risk of off-tumor effects. Conversely, tumor-associated antigens, while not exclusive to malignant cells, are often overexpressed in tumors and serve as additional targets to mobilize T cell cytotoxicity. This dual targeting strategy underscores the complexity of immune surveillance within heterogeneous tumor ecosystems.

Despite the potent capabilities of T cells, tumors have evolved sophisticated mechanisms to evade immune detection and destruction. Among these, the induction of T cell exhaustion within the immunosuppressive tumor microenvironment (TME) significantly impairs the effector functions of infiltrating lymphocytes. This exhaustion is characterized by sustained expression of inhibitory receptors and diminished cytokine production, effectively blunting the anti-tumor immune response and fostering tumor progression under an immunologically suppressive milieu.

Moreover, tumors can undergo immunoediting, a dynamic process wherein cancer cells lose or alter their antigenic profiles to escape T cell recognition. This antigenic plasticity poses a substantial barrier to effective immunotherapy, necessitating strategies that address tumor heterogeneity and adaptability. Physical barriers within the TME, including aberrant vasculature and stromal components, further obstruct T cell infiltration and limit their capacity to exert cytotoxic effects at tumor sites.

Modern immunotherapeutic approaches leverage the diverse functionalities of T cells to circumvent tumor evasion. Antibody-based therapies, such as immune checkpoint inhibitors, alleviate inhibitory signals like PD-1/PD-L1 and CTLA-4 pathways, reinvigorating exhausted T cells. Bispecific T cell engagers (BiTEs) bridge T cells to tumor cells, facilitating direct cytotoxic engagement. These modalities have revolutionized treatment paradigms, achieving remarkable clinical responses in several cancer types.

Adoptive Cell Transfer (ACT) represents another therapeutic frontier in which autologous or allogeneic T cells are expanded or genetically engineered ex vivo and then infused back into patients. Tumor-Infiltrating Lymphocyte (TIL) therapy involves isolating and expanding naturally occurring tumor-specific T cells. Genetically modified therapies, including Chimeric Antigen Receptor (CAR) T cells and T Cell Receptor-engineered (TCR-T) cells, enhance recognition capabilities against specific tumor antigens, opening new avenues for hematologic and solid tumor treatment.

Cancer vaccines are designed to prime the immune system by presenting tumor antigens, inducing robust, antigen-specific T cell responses. These vaccines serve as both prophylactic and therapeutic tools, aiming to generate durable immunity against existing tumors or prevent tumor recurrence. Despite their promise, the immunosuppressive TME and antigenic variability continue to challenge vaccine efficacy in clinical contexts.

Professor Tao Dong emphasizes the necessity of combination therapies that integrate these distinct immunotherapeutic modalities. Such regimens are designed to conduct a multifaceted assault on cancer—overcoming antigen escape, reversing T cell exhaustion, and dismantling the physical and immunological barriers of the TME. The orchestration of these therapies holds the key to overcoming the limitations of monotherapies and improving patient outcomes comprehensively.

Cutting-edge research efforts are focused on two critical axes that could revolutionize T cell immunotherapy. First, the identification and cataloging of precise tumor antigens, alongside sophisticated T cell receptor (TCR) libraries, aim to tailor treatments uniquely suited to individual tumor antigen landscapes. Second, unraveling the nuanced biology of T cell subsets and their functional states promises to yield biomarkers for optimizing patient selection and predicting therapeutic responses, thus personalizing immunotherapy at an unprecedented scale.

This comprehensive understanding of T cell-mediated immunity and the multifarious avenues of immunotherapeutic intervention form a robust framework for pioneering more effective, resilient cancer treatments. Researchers and clinicians are poised to translate these insights into clinical success, addressing enduring challenges such as tumor heterogeneity, immune suppression, and therapy-induced toxicities.

As the field advances, technological innovations including single-cell omics and spatial transcriptomics are refining our ability to dissect T cell-tumor interactions in situ, providing granular insights into immune evasion and therapeutic resistance. These precision tools facilitate the rational design of next-generation immunotherapies, with the potential to unlock enduring remission and possibly cure for diverse malignancies.

In sum, leveraging T cells for cancer immunotherapy embodies a paradigm shift, harnessing the specificity, adaptability, and potency of adaptive immunity. The convergence of molecular understanding, engineering prowess, and clinical acumen heralds a new era in oncology—one where immune cells are not just defenders but powerful allies in the quest to conquer cancer.

Subject of Research: Not applicable

Article Title: Leveraging T cells for cancer immunotherapy

News Publication Date: 21-Oct-2025

References: DOI: 10.1007/s44466-025-00007-z

Image Credits: Professor Tao Dong Team, University of Oxford, Oxford, UK

Keywords: Cancer immunotherapy, T lymphocytes, Immunity, Tumor microenvironments, Antigens, Neoantigens, Cancer vaccines, Cancer treatments, Biomarkers, Cell biology